Analysts Expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to Post -$0.37 EPS

Wall Street analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) will post ($0.36) earnings per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for BioCryst Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.51) and the highest estimate coming in at ($0.20). BioCryst Pharmaceuticals posted earnings of ($0.24) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 50%. The business is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full-year earnings of ($1.37) per share for the current financial year, with EPS estimates ranging from ($1.94) to ($1.00). For the next fiscal year, analysts forecast that the business will report earnings of ($0.66) per share, with EPS estimates ranging from ($1.38) to $0.75. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) last released its quarterly earnings data on Wednesday, February 23rd. The biotechnology company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.09). The company had revenue of $47.16 million during the quarter, compared to analyst estimates of $48.18 million.

BCRX has been the subject of a number of recent analyst reports. Bank of America downgraded BioCryst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $21.00 to $14.00 in a report on Monday, April 11th. Oppenheimer lowered their price target on BioCryst Pharmaceuticals from $16.00 to $13.00 and set an “outperform” rating for the company in a report on Friday. StockNews.com downgraded BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Royal Bank of Canada lowered their price target on BioCryst Pharmaceuticals from $16.00 to $14.00 and set a “sector perform” rating for the company in a report on Tuesday, April 12th. Finally, Barclays downgraded BioCryst Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price target for the stock from $22.00 to $13.00 in a report on Monday, April 18th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $17.67.

NASDAQ BCRX opened at $8.39 on Friday. The stock has a 50-day simple moving average of $13.22 and a 200 day simple moving average of $13.92. The company has a market capitalization of $1.56 billion, a PE ratio of -7.84 and a beta of 2.51. BioCryst Pharmaceuticals has a 12 month low of $7.61 and a 12 month high of $19.99.

In related news, Director George B. Abercrombie sold 5,000 shares of the stock in a transaction that occurred on Tuesday, February 15th. The stock was sold at an average price of $18.50, for a total transaction of $92,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Helen M. Thackray sold 7,600 shares of the stock in a transaction that occurred on Friday, April 1st. The shares were sold at an average price of $16.20, for a total value of $123,120.00. Following the transaction, the insider now directly owns 136,400 shares of the company’s stock, valued at $2,209,680. The disclosure for this sale can be found here. 4.80% of the stock is owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in BCRX. J.W. Cole Advisors Inc. increased its stake in shares of BioCryst Pharmaceuticals by 2.0% during the fourth quarter. J.W. Cole Advisors Inc. now owns 36,800 shares of the biotechnology company’s stock worth $510,000 after purchasing an additional 735 shares during the period. Semmax Financial Advisors Inc. increased its stake in shares of BioCryst Pharmaceuticals by 389.6% during the first quarter. Semmax Financial Advisors Inc. now owns 1,699 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,352 shares during the period. Kalos Management Inc. increased its stake in shares of BioCryst Pharmaceuticals by 7.0% during the fourth quarter. Kalos Management Inc. now owns 25,359 shares of the biotechnology company’s stock worth $340,000 after purchasing an additional 1,659 shares during the period. E Fund Management Co. Ltd. increased its stake in shares of BioCryst Pharmaceuticals by 11.8% during the first quarter. E Fund Management Co. Ltd. now owns 16,641 shares of the biotechnology company’s stock worth $271,000 after purchasing an additional 1,756 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its stake in shares of BioCryst Pharmaceuticals by 2.8% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 67,065 shares of the biotechnology company’s stock worth $894,000 after purchasing an additional 1,800 shares during the period. Hedge funds and other institutional investors own 63.86% of the company’s stock.

About BioCryst Pharmaceuticals (Get Rating)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Further Reading